SYNthesis med chem has joined Lean Life Science’s Oncology Development Programme (ODP2), a collaboration with four of the top ten global pharma, Cancer Research UK’s Cancer Research Horizons, Manchester Cancer Research Centre (MCRC) and over 20 specialist contract research organisations. ODP2 is aimed at identifying, de-risking and catalysing commercially viable UK-based innovations to improve diagnosis and treatment of cancer and accelerate the translation of emerging cancer research for patient benefit.
Lean Life Science is an organisation dedicated to catalysing innovation in life science through partnership and Oncology Development Programme (ODP2) is its newly opened flagship programme. ODP2 will give the next big UK-based breakthroughs in oncology access to bespoke expert scientific review, clinical study design, technical gap analysis, financial / business value modelling and integrated project planning.
Up to 100 oncology innovations, from academics and early-stage companies, will be selected by the Programme Faculty Panel, to participate in process stages which will provide an insight into the highly successful Lean Life Science approach to developing oncology assets and securing investment and an opportunity to engage directly with pharma and CRO experts, including SYNthesis med chem, part of Viva Biotech.
Selected participants will progress to working closely with the ODP2 partners to create and validate integrated plans, that we are accustomed to SYNthesis med chem (Viva Biotech), and which are necessary to ensure successful development and attract potential funding.
For further information please contact firstname.lastname@example.org and see: